🔥 Fat Loss & MetabolismPhase III

Cagrilintide

AM833 · Long-acting amylin analog · CagriSema component

Long-acting amylin analog with additive weight loss when combined with semaglutide

Typical Dose

1.2 mg once weekly

Route

Subcutaneous

Frequency

Once weekly

Cycle

12-32 weeks

Overview

Cagrilintide is a long-acting synthetic analog of amylin, a pancreatic hormone co-secreted with insulin. When combined with semaglutide (as CagriSema), Phase 2 trials showed additive weight loss effects exceeding 15% over 32 weeks. Amylin analogs work through complementary pathways to GLP-1 agonists, making the combination particularly potent for metabolic research.

Key Benefits

Appetite suppression via amylin receptor activation
Slowed gastric emptying
Glucagon suppression
Additive weight loss when combined with semaglutide
Improved postprandial glucose control
Once-weekly dosing convenience

Mechanism of Action

Cagrilintide acts on amylin receptors in the area postrema and hypothalamus to reduce food intake, slow gastric emptying, and suppress glucagon secretion. Its long half-life (approximately 7 days) allows for once-weekly dosing. The mechanism is complementary to GLP-1 agonism, targeting different neural circuits for appetite suppression.

Dosing Protocol

Typical Dose

1.2 mg once weekly

Dose Range

0.3-2.4 mg/week

Frequency

Once weekly

Route

Subcutaneous injection

Cycle Length

12-32 weeks

CLINICAL NOTES

Start at 0.3 mg weekly for 4 weeks. Titrate slowly to minimize GI side effects. Often combined with semaglutide.

Reconstitution calculator and cycle planner pre-filled with Cagrilintide defaults

Side Effects & Safety

Nausea
Vomiting
Diarrhea
Injection site reactions
Decreased appetite

IMPORTANT DISCLAIMER

This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol. Individual responses vary and medical supervision is recommended.

Research References

Frequently Asked Questions

Quick Reference

CategoryFat Loss & Metabolism
Research StatusPhase III
Typical Dose1.2 mg once weekly
RouteSubcutaneous
Cycle12-32 weeks

Community Reviews

Real experiences from the Peptide Insights community

Have experience with Cagrilintide?

Log in to share your experience and help the community.

Log In to Review

No reviews yet for Cagrilintide

Be the first to share your experience.